Sivakesava Sakhamuri - 04 Nov 2026 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Reporting relationship: Chief Technical Officer
Issuer ticker: CRSP
Reported as of: 04 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Nov 2026, 17:35:03 UTC
Prior SEC filing: 02 Nov 2026
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Ryland Waldinger, attorney-in-fact

Filing notes and source

Key filing fact

Sivakesava Sakhamuri filed Form 4 for CRISPR Therapeutics AG (CRSP) on 06 Nov 2026.

Key facts

This page summarizes Sivakesava Sakhamuri's Form 4 filing for CRISPR Therapeutics AG (CRSP).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 06 Nov 2026, 17:35.

Change

Previous filing in this sequence was filed on 02 Nov 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002158086 Primary reporting owner

Sakhamuri Sivakesava

Relationship: Chief Technical Officer
Address: C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON
Signature: /s/ Elizabeth Ryland Waldinger, attorney-in-fact
Signature date: 06 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRSP transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +90,000
Change %
Price: $0.000000^*
Shares after: 90,000
Date: 04 Nov 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 90,000
Exercise price: $51.78
Footnotes: F1

CRSP transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +40,000
Change %
Price: $0.000000^*
Shares after: 40,000
Date: 04 Nov 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 40,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This option was granted on November 4, 2026 with respect to 90,000 Common Shares. 25% of the shares shall vest on November 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Footnote F3

This restricted stock unit award was granted on November 4, 2026 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on November 2, 2027, (ii) one quarter of the shares vesting on November 2, 2028, (iii) one quarter of the shares vesting on November 2, 2029, and (iv) one quarter of the shares vesting on November 2, 2030.